By Cocer Peptides 
1 month ago
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
Dermorphin is a potent opioid peptide isolated from the skin of certain frog species.
The Mechanism of Dermorphin's Analgesic Effects
Interaction with Opioid Receptors
Dermorphin primarily exerts its analgesic effects by interacting with the μ-opioid receptor (MOP). The μ-opioid receptor is a key member of the opioid receptor family and plays a crucial role in pain modulation. Dermorphin and its analogues can specifically bind to the MOP receptor, akin to a key fitting into a lock, thereby activating downstream signaling pathways. [Cys (ATTO 488) 8] Dermorphin - NH₂ (DermATTO488), a novel fluorescent Dermorphin analog based on ATTO488, binds to HEK and CHO cells expressing human MOP receptors and exhibits similar binding characteristics to Dermorphin. It stimulates G protein binding, promotes GTPγ[35S] binding, thereby activating related signal transduction, and ultimately inhibits pain signal transmission. Dermorphin also stimulates ERK1/2 phosphorylation, further influencing intracellular biological processes and participating in the regulation of analgesic effects.
Inhibition of pain signal transmission at the spinal cord level
Experimental studies have shown that Dermorphin significantly inhibits pain signal transmission at the spinal cord level. In experiments, intravenous infusion of 0.16 mg/kg Dermorphin induced a significant and sustained increase in the nociceptive flexion reflex threshold in healthy volunteers, and this effect was equally pronounced in subjects with complete chronic spinal cord injury, indicating that Dermorphin primarily inhibits nociceptive transmission at the spinal cord level. This mechanism of action may be related to Dermorphin's regulation of neurotransmitter release within the spinal cord or its direct action on spinal cord neurons. The spinal cord serves as a critical hub for pain signal transmission, and Dermorphin's modulation of its function effectively blocks the upward transmission of pain signals to the brain, thereby achieving analgesic effects.
Unique receptor action characteristics
Although naloxone can completely antagonize the effects of morphine and opioid analogs, it can only partially (approximately 50%) reverse Dermorphin's inhibitory effect on nociceptive spinal reflexes. This suggests that Dermorphin interacts with different groups of spinal opioid receptors when inducing analgesia, and its mechanism of action differs from that of traditional opioid drugs. This mode of action confers certain advantages in analgesic applications, such as reducing common side effects associated with traditional opioid drugs.
Analgesic Performance of Dermorphin in Animal Experiments
Effective Analgesia in Multiple Animal Models
In various animal pain models, Dermorphin demonstrated potent analgesic effects. In experiments such as tail-flick, hot plate, tail pinch, formalin, and acetic acid writhing tests, intraperitoneal administration of Dermorphin and its related peptides reduced animals' sensitivity to pain and increased their pain thresholds. These experiments simulated pain of varying degrees and types, comprehensively validating Dermorphin's analgesic capabilities. In the hot plate test, after administering Dermorphin to animals, the latency period for licking their paws or jumping was significantly prolonged, indicating a weakened pain response to thermal stimulation, thereby demonstrating Dermorphin's excellent analgesic effect.
Comparative Advantages Over Other Analgesic Drugs
Compared to traditional analgesic drugs such as morphine, Dermorphin exhibits significant advantages in certain aspects. In animal models, after intracerebroventricular administration, Dermorphin exhibited more selective and potent analgesic effects than morphine, with a longer duration of action. Some synthesized Dermorphin tetrapepetides also demonstrated high analgesic activity, with analgesic potency approximately 1,500 times and 17 times that of morphine after intracerebroventricular or subcutaneous administration in mice, respectively. These advantages offer promising prospects for the clinical application of Dermorphin in analgesia, potentially addressing shortcomings of traditional analgesic drugs, such as insufficient analgesic efficacy or duration.
Research and Application Exploration of Dermorphin in Humans
Early Clinical Trial Results
In 1985, a randomized, placebo-controlled clinical trial on the use of Dermorphin for postoperative pain demonstrated that Dermorphin administered via intrathecal injection significantly outperformed placebo and morphine (used as a reference compound) in terms of analgesic efficacy. This landmark study provided crucial supporting evidence for the clinical application of Dermorphin in analgesia, highlighting its immense potential in postoperative pain management.
Potential Application Scenarios
Postoperative Pain Management: Surgical trauma can cause severe postoperative pain, significantly impacting patients' recovery and quality of life. Dermorphin's demonstrated efficacy in alleviating postoperative pain in early clinical trials positions it as a promising new option for postoperative analgesia. Compared to traditional postoperative analgesic drugs, its unique mechanism of action and advantages—such as reduced risk of drug tolerance and dependence—offer patients a safer and more effective analgesic solution.
Chronic pain treatment: For patients with chronic pain, especially those who have poor responses to traditional analgesic drugs or experience significant side effects, Dermorphin may serve as a valuable alternative treatment option. In the management of chronic pain in cancer patients, current treatment methods still have certain limitations. The emergence of Dermorphin brings new hope to this patient population. Its long-lasting analgesic effects can better control persistent pain in cancer patients and improve their quality of life.
Palliative care: In palliative care settings, alleviating patients' pain is the top priority. Dermorphin's potent analgesic properties make it a promising candidate for alleviating end-of-life pain in palliative care. Through appropriate administration methods and dose adjustments, it can help patients reduce suffering and enhance comfort during the final stages of life.
Conclusion
As a substance with a unique analgesic mechanism and significant analgesic effects, Dermorphin holds promising applications in the field of pain management.
Sources
[1] Giakomidi D, Bird M F, McDonald J, et al. Evaluation of [Cys(ATTO 488)8]Dermorphin-NH2 as a novel tool for the study of μ-opioid peptide receptors[J]. Plos One, 2021,16(4):e250011.DOI:10.1371/journal.pone.0250011.
[2] Hesselink J, Schatman M E. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation[J]. Journal of Pain Research, 2018,11:2991-2995.DOI:10.2147/JPR.S186082.
[3] Guzevatykh L S, Voronina T A, Emel'Ianova T G, et al. Comparative analysis of analgesic activities of dermorphin, [DPro6]-dermorphin, and their C-terminal tripeptides[J]. Izv Akad Nauk Ser Biol, 2007(5):577-582. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18038625&query_hl=1
[4] Sandrini G, Degli U E, Salvadori S, et al. Dermorphin inhibits spinal nociceptive flexion reflex in humans[J]. Brain Research, 1986,371(2):364-367.DOI:10.1016/0006-8993(86)90376-8.
[5] Salvadori S, Marastoni M, Balboni G, et al. Synthesis and opioid activity of dermorphin tetrapeptides bearing D-methionine S-oxide at position 2[J]. Journal of Medicinal Chemistry, 1986,29(6):889-894.DOI:10.1021/jm00156a003.
Product available for research use only:
